Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS ...

Long Trade IdeaEnter your long position between 297.78 (yesterday's intra-day low) and 304.07 (yesterday's intra-day high).Market Index Analys ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Wall Street expects a year-over-year decline in earnings on higher revenues when MannKind (MNKD) reports results for the ...

Insmed, a biopharmaceutical specialist in rare diseases, is stealing the spotlight in 2025 with a stunning 62% gain, ...

Bain Capital will make a $300 million funding in the new company, while BMY will out-license five immunology candidates.

Valley Wealth Managers Inc. just upped their Amgen game by 8.1% this quarter, now holding a cool $27.15 million worth of ...

Mediolanum International Funds Ltd has supercharged its investment in Regeneron Pharmaceuticals, increasing its stake by a ...